According to a recent analysis by Future Market Insights (FMI), the global protein diagnostics market is poised for substantial growth over the coming decade, with an estimated valuation reaching US$ 8.3 billion by 2033, up from US$ 4.7 billion in 2022. This growth trajectory reflects the increasing demand for advanced diagnostic tools and solutions, propelled by the rising need for early disease detection and the rapid pace of innovation in biotechnology.
The FMI report highlights several critical factors contributing to this upward trend, including the heightened focus on personalized medicine, advances in protein biomarker research, and technological innovations in diagnostic platforms. As healthcare providers seek to improve early diagnosis and treatment effectiveness, the market for protein diagnostics is anticipated to expand, addressing a range of conditions from infectious diseases to cancer and chronic illnesses.
Key Insights from FMI’s Protein Diagnostics Market Analysis:
- Market Value and Growth: The protein diagnostics market is projected to grow steadily, driven by increased adoption in clinical laboratories and research settings.
- Technological Advancements: Innovations in diagnostic assays, including high-sensitivity tests and multiplexed assays, are enhancing the detection and quantification of protein biomarkers, improving accuracy and reducing diagnostic timelines.
- Regional Growth: North America is expected to maintain its leadership position due to advanced healthcare infrastructure and high R&D investment, while Asia-Pacific is likely to witness notable growth due to expanding healthcare access and rising awareness about early diagnostics.
Future Outlook
The global protein diagnostics market is set for accelerated growth as researchers and healthcare providers increasingly utilize advanced diagnostic technologies to enhance patient outcomes. FMI’s report anticipates continued investments in research and development, leading to the introduction of cutting-edge diagnostic solutions that support early intervention and targeted treatment approaches.
Key Takeaways:
- Reagent Kits are the leading segment of products among end users and held about 62.3% market share in 2022, the growing number of infectious diseases has led to their high adoption of reagent kits.
- By sample, serum is the most compatible because it is an abundant source of protein, accessibility, and stability than other samples. The segment contributes 35.4% value share to the global market in 2022.
- Disease diagnosis held the dominant market share of 85.0% among other applications in 2022, due to the recent rise of infectious diseases and hospital-acquired infections.
- Turbidimetry held a market share of 76.3% in 2022, owing to the factor that it shortens the assay time by enabling faster binding of the antibodies and antigen
- Hospital segment by end user accounted for a revenue share of 36.9% in the global market at the end of 2022. Hospitals are built to provide coordinated care across departments and specializations, which can be useful when many diagnostic tests are required to reach a diagnosis.
- By region, North America is leading in the global Protein Diagnostics market and is expected to continue to do so with a projected CAGR rate of 6.7% during the forecasted years.
“Increasing adoption of protein diagnostic testing for the identification of underlying diseases and early detection of chronic disease are the key drivers of the Protein Diagnostics market,” says an analyst at Future Market Insights (FMI).
What are the Key Opportunities in the Protein Diagnostics Market?
Clinical diagnostics play a crucial role in healthcare, particularly in the detection and chronic disease such as the management of cancer, which is a leading cause of mortality worldwide.
Early detection through effective prevention, screening, and diagnostic measures can significantly reduce treatment costs and save lives. Diagnostic tests can provide important information about a patient’s health status, including their risk for cancer, disease stage, and prognosis. Promoting awareness of the disease and its symptoms can encourage patients to take advantage of preventive measures and seek medical care early.
Protein tests can detect these changes in protein levels, providing early indications of disease before symptoms manifest. For example, elevated levels of prostate-specific antigen (PSA) in the blood can be an early indicator of prostate cancer, and abnormal levels of protein in cerebrospinal fluid (CSF) can be a sign of neurological disorders such as Alzheimer’s disease or multiple sclerosis.
C-reactive protein (CRP) is also a useful biomarker for monitoring other inflammatory conditions, such as rheumatoid arthritis and inflammatory bowel disease.
The CRP test has found an important role in COVID monitoring. Along with that detection of IgM and IgG provide a simple, quick, and accurate detection method for suspected COVID-19 cases. This increased demand for protein diagnostics kits, driving growth in the global protein diagnostics market.
Increased regular health check-ups in patients will pave the way for protein diagnostics, ultimately leading to the introduction of technologically advanced products into the market.
Competitive Landscape
The industry’s major players are concentrating on diversifying their product offerings to boost their market share in the protein diagnostics sector and broaden their presence in developing nations. Pricing strategies, market strategies, technology improvements, regulatory compliance, and acquisition and distribution agreements with other companies to extend their business are among the primary approaches used by manufacturers to acquire a competitive edge in the market.
For instance:
- Roche and Eli Lilly and Company collaborated on Mar 2023 to develop Elecsys® Amyloid Plasma Panel (EAPP) – (Roche’s Brand). The EAPP is a cutting-edge blood test created to help with early Alzheimer’s disease diagnosis.
- The Binding Site Group (The Binding Site), a world leader in specialty diagnostics, was acquired by Thermo Fisher Scientific Inc. in January 2023.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the protein diagnostics market space, which are available in the full report
Key Companies Profiled
Beckman Coulter, Inc.; Siemens Healthineers; F. Hoffmann-La Roche Ltd.; Agilent Technologies, Inc.; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Elabscience Biotechnology Inc.; Goldsite Diagnostics Inc.; Getein Biotech, Inc.; Randox Laboratories Ltd.; Hipro Biotechnology Co., Ltd.; Beijing Strong Biotechnologies, Inc.
Key Segments Covered in Protein Diagnostics Industry Research
By Product:
- Analyzers
- Reagents
- Albumin Test Kits
- Alpha-1-Microglobulin Albumin Test Kits
- Alpha-2-Macroglobulin Albumin Test Kits
- C-Reactive Protein Test Kits
- Fibrinogen Test Kits
- Fibronectin Test Kits
- Haptoglobin Test Kits
- Kappa Light Chains Kits
- Lambda Light Chains Kits
- Transferrin Test Kits
- Alpha-1-Acid Glycoprotein Test Kits
- Alpha-1-Antitrypsin Test Kits
- Apolipoprotein B Test Kits
- Cystatin Test Kits
- Ferritin Test Kits
- Immunoglobulin Test Kits
- IgA
- IgE
- IgG
- IgG 1
- IgG 2
- IgG 3
- IgG 4
- IgM
- Lipoprotein Test Kits
- Others
- Calibrators & Controls Kits/Reagents
By Sample:
- Serum
- Plasma
- Urine
- Cerebrospinal Fluid
- Others
By Application:
- Drug Discovery and Development
- Antigen-Antibody Reaction
- Immunocomplex Reaction
- Protein Measurement
- Others
- Disease Diagnosis
- Cancer
- Infectious Disease
- Blood Coagulation
- Renal Function
- Liver Diseases
- Autoimmune Disorder
- Others
- Other Applications
By Technology:
- Turbidimetry
- Nephelometry
By End User:
- Hospital
- Diagnostic Labs
- Reference Labs
- Speciality Clinics/Standalone
By Region:
- North America
- Latin America
- China
- East Asia
- South Asia and the Pacific
- Western Europe
- Eastern Europe
- Central Asia
- Russia and Belarus
- Balkan and Baltic Countries
- Middle East and Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube